Yvonne Greenstreet, Alnylam CEO (Suzanne Kreiter/The Boston Globe via Getty Images)
March 9, 2023 03:02 PM EST
Pharma
Marketing

Al­ny­lam ex­pands RNAi com­mer­cial­iza­tion deal in Eu­rope

Nicole DeFeudis

Editor

Al­ny­lam is dou­bling down on a part­ner­ship to ex­pand its com­mer­cial pres­ence in Eu­rope, as it forges ahead on for­mer CEO John Maraganore’s mis­sion to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times